Would Harry Represent Me?
A Thought Leader, A Change Maker, An Innovator.
For over two decades, Harry Nelson has been consulted by healthcare organizations, employers, and even state and federal regulators on complex questions about the future of U.S. healthcare, with particular focus on behavioral health and telehealth issues. His clients have included nearly every segment of the healthcare and life science ecosystems, including health systems, investors, technology companies, clinical researchers, health facilities, health professionals, and drug and device makers. Harry has been called on to resolve critical issues emerging in the interaction between healthcare providers and government or payors, including issues related to fraud and abuse, clinical safety, licensing, operations, and reimbursement. He is frequently asked to to advise strategically on navigating a compliant path in dealing with new models of care. In addition to his regulatory team, Harry has also built one of the most innovative and respected healthcare and life science law firms in the country, Nelson Hardiman, providing a team of over 30 attorneys taking on bet-the-company litigation and transactions.
In addition to nuanced legal analysis, Harry is regularly asked to provide advisory services on developing alternative solutions to pressing healthcare challenges, including the search for new modes of care and new therapeutic agents. Among other issues, Harry has counseled clients on issues related to genomic medicine and cannabinoid research. Harry has been an advocate for expanding research opportunities in these and other areas in the quest for new solutions to the opioid crisis.
Harry’s areas of expertise include:
- DEA and medical board opioid and drug prescribing standards and compliance
- Behavioral health and addiction treatment standards and compliance
- Healthcare organizational strategy and compliance (hospitals, post-acute, behavioral health, residential care, pharmacy, lab) and health professional licensing
- Healthcare operational compliance (data privacy and security, medications, corporate practice of medicine, patient/resident rights, and other risk management and liability issues)
- Healthcare reimbursement strategy and compliance
- Telehealth and retail medical models
- FDA/DEA clinical research requirements, medical device, and biologic product and cannabis-related compliance
- HIPAA and Title 42 data privacy and security compliance
- Corporate compliance and board governance
- Medicare and Medicaid compliance
Founded and led by Harry Nelson, the Nelson Hardiman healthcare regulatory and life sciences law firm advises on regulatory compliance and business strategy, represents clients in bet-the-company healthcare litigation and government investigations, and handles complex healthcare and life sciences transactions for investors, lenders, and other stakeholders. Annually ranked among the nation’s top law firms in its specialties, Nelson Hardiman represents a wide variety of clients who need the best guidance on the most challenging healthcare legal and regulatory problems.
A national trade association that provides education and advocacy for over 30,00 behavioral health and addiction treatment professionals and organizations. Harry chairs the board and works to develop and advance industry compliance, ethics, and clinical standards that improve the quality of care and enable providers to survive and thrive in a fast-changing business landscape.
Harry helped launch this innovative regulatory compliance consulting and outsourcing firm that serves a wide range of healthcare organizations nationally. Compliagent collaborates with clients to help them thrive in today’s complex business and regulatory compliance environment.
Harry was a driving force behind a larger team that established AHC to provide capital and strategic support to entrepreneurs and mature organizations focused on or responding to the pressures of healthcare transformation. Led by experienced hedge fund managers, Adaptive’s expert, industry-focused financial insights and strategic guidance have proved crucial to identifying, negotiating and closing transactions in healthcare and life sciences.